Transcranial magnetic stimulation during pregnancy: An alternative to antidepressant treatment?
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on transcranial magnetic stimulation during pregnancy with Ob.Gyn News on May 4th.
Zuranolone Improves Anxiety Symptoms and Insomnia in Women with Postpartum Depression
In women with postpartum depression, zuranolone was associated with concurrent improvements in depression, anxiety symptoms, and insomnia beginning at day 3.
Maternal Mental Health Awareness Week: May 1-7, 2023
May 4, 2022 is World Maternal Mental Health Day, coming together to increase awareness of perinatal mood and anxiety disorders.
New Research from the CWMH: More Data on the Reproductive Safety of Lurasidone and Quetiapine
New findings from the National Pregnancy Registry for Atypical Antipsychotics provide reassuring data regarding the safety of prenatal exposure to lurasidone and quetiapine in a sample of well-characterized participants.
What Has a Greater Effect on Children’s Behavior: Prenatal Exposure to Antidepressants or Maternal Depression?
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
Is it Safe to Use Atomoxetine (Strattera) During Pregnancy?
Based on this large cohort study including 990 pregnancies with first trimester exposure to atomoxetine, the researchers observed no increase in major congenital malformations overall and no statistically increased risk estimates for cardiac or limb malformations.